Kamada (KMDA) Competitors $7.00 +0.01 (+0.07%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. CNTA, ADPT, ETNB, JANX, MESO, EVO, SPRY, OCUL, VERA, and ANIPShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Centessa Pharmaceuticals (CNTA), Adaptive Biotechnologies (ADPT), 89bio (ETNB), Janux Therapeutics (JANX), Mesoblast (MESO), Evotec (EVO), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Centessa Pharmaceuticals Adaptive Biotechnologies 89bio Janux Therapeutics Mesoblast Evotec ARS Pharmaceuticals Ocular Therapeutix Vera Therapeutics ANI Pharmaceuticals Kamada (NASDAQ:KMDA) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Which has stronger valuation and earnings, KMDA or CNTA? Kamada has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$167.24M2.41$8.28M$0.2924.12Centessa Pharmaceuticals$15M111.65-$151.09M-$1.81-6.93 Do analysts rate KMDA or CNTA? Kamada presently has a consensus target price of $14.67, indicating a potential upside of 109.67%. Centessa Pharmaceuticals has a consensus target price of $27.89, indicating a potential upside of 122.40%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KMDA or CNTA more profitable? Kamada has a net margin of 9.92% compared to Centessa Pharmaceuticals' net margin of 0.00%. Kamada's return on equity of 6.30% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Centessa Pharmaceuticals N/A -52.13%-38.01% Does the MarketBeat Community prefer KMDA or CNTA? Kamada received 291 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 66.26% of users gave Kamada an outperform vote while only 61.67% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32866.26% Underperform Votes16733.74% Centessa PharmaceuticalsOutperform Votes3761.67% Underperform Votes2338.33% Do institutionals & insiders have more ownership in KMDA or CNTA? 20.4% of Kamada shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer KMDA or CNTA? In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Kamada. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 3 mentions for Kamada. Centessa Pharmaceuticals' average media sentiment score of 1.20 beat Kamada's score of 0.61 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, KMDA or CNTA? Kamada has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. SummaryKamada beats Centessa Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$401.79M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio24.968.7927.2020.17Price / Sales2.40263.51412.92161.94Price / Cash17.9065.8538.2534.64Price / Book1.646.677.114.72Net Income$8.28M$143.49M$3.23B$247.80M7 Day Performance4.95%5.15%3.77%2.76%1 Month Performance1.60%15.43%13.33%9.71%1 Year Performance37.06%6.02%32.02%14.51% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.2979 of 5 stars$7.00+0.1%$14.67+109.7%+33.1%$402.25M$167.24M24.98360News CoverageCNTACentessa Pharmaceuticals3.4603 of 5 stars$11.94+0.2%$27.89+133.6%+33.5%$1.59B$15M-7.80200Positive NewsHigh Trading VolumeADPTAdaptive Biotechnologies2.9596 of 5 stars$10.45+3.6%$9.83-5.9%+199.7%$1.59B$189.53M-9.59790Positive NewsETNB89bio2.4514 of 5 stars$10.57+3.1%$26.43+150.0%+21.4%$1.54BN/A-3.6340Positive NewsAnalyst RevisionGap UpJANXJanux Therapeutics1.587 of 5 stars$25.94-1.0%$95.25+267.2%-39.5%$1.54B$9.34M-22.1730Positive NewsAnalyst RevisionMESOMesoblast1.6891 of 5 stars$11.85+0.5%$18.00+51.9%+77.0%$1.51B$5.67M0.0080News CoveragePositive NewsAnalyst RevisionGap DownEVOEvotec1.4836 of 5 stars$4.12+1.7%$5.93+44.0%-11.2%$1.46B$788.22M0.004,200SPRYARS Pharmaceuticals2.8506 of 5 stars$14.53+0.3%$31.00+113.4%+62.0%$1.43B$97.12M-28.4990Positive NewsAnalyst RevisionOCULOcular Therapeutix3.865 of 5 stars$8.90-1.3%$16.25+82.6%+78.9%$1.42B$59.65M-6.74230VERAVera Therapeutics2.8059 of 5 stars$22.19-2.2%$65.00+192.9%-42.0%$1.42BN/A-8.5040Analyst RevisionHigh Trading VolumeANIPANI Pharmaceuticals4.5137 of 5 stars$63.18+2.0%$80.13+26.8%-3.2%$1.37B$674.07M-114.87600Positive News Related Companies and Tools Related Companies Centessa Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives 89bio Alternatives Janux Therapeutics Alternatives Mesoblast Alternatives Evotec Alternatives ARS Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Vera Therapeutics Alternatives ANI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KMDA Stock Free KMDA Stock Alerts